

Supplemental material

Supplemental Table 1: Clinical data related to the day of sampling (baseline sample)

Sampling	SARS-CoV-2^{neg} (n = 22)	SARS-CoV-2⁺ (n = 50)	Statistical analysis
Time from onset of COVID-19 symptoms to baseline sampling, median day (range)	NA	12.0 (3-23)	NA
Time from first documented positive SARS-CoV-2 PCR to baseline sampling, median day (range)	NA	6.5 (2-23)	NA
Time from hospital admission to baseline sampling, median day (range)	3.5 (1-22)	4.5 (1-61)	# p = 0.4209
O ₂ requirements at time of baseline sampling, n (%)	13/22 none (59.1) 4/22 low flow (18.2) 5/22 high flow/invasive (22.7)	21/50 none (42.0) 8/50 low flow (16.0) 21/50 high flow/invasive (42.0)	‡ p = 0.3418
In ICU at time of baseline sampling n (%)	10/22 (45.5)	23/50 (46.0)	+ p > 0.9999

n: number of patients in specified category; NA: not applicable

+ Fisher's exact test; # Mann-Whitney U test; ‡ Chi-squared test

Supplemental Table 2: Granulocyte & monocyte-oriented panel (S1)


Fluorochrome	Antigen	Manufacturer/Catalogue #	Clone
FITC	CD66b	BD-555724	G10F5
PE	CD33	BioLegend-303404	WN53
APC	ICAM-1	BD-559771	HA58
v450	CD15	BD-561584	HI98
AF700	HLA-DR	BD-560743	G46-6
PE-CF594	CD16	BD-562320	3G8
PerCP-Cy5.5	CCR2	BD-357203	K036C2
Pe-Cy7	CD11b	eBioscience-25-0118-42	ICRF44
BV605	CD56	BioLegend-318334	HCD56
BV785	CD62L	Biolegend-304830	DREG-56
BV711	CD8	BD-563677	RPA-T8
BUV395	CD3	BD-563546	UCHT1
BUV496	CD4	BD-612936	SK3
BUV737	CD14	BD-564444	M5E2

Supplemental Table 3: NK Cell/Dendritic Cell-oriented Panel (S2)


Fluorochrome	Antigen	Manufacturer/Catalogue #	Clone
FITC	CD1a	BD-555806	HI149
PE	TCR iNKT	BioLegend-342904	6B11
APC	MCAM	Miltenyi -130-120-701	541-10B2
BV421	CD123	BD-562517	9F5
APC-R700	CD11c	BD-566610	3.9
PE-CF594	TCR gam-del	BD-562511	B1
PerCP-Cy5.5	CD45RO	BD-560607	UCHL1
Pe-Cy7	CD56	BD-557747	B159
BV605	CD19	BioLegend-302244	HIB19
BV786	CD16	BD-563690	3G8
BV711	CD8	BD-563677	RPA-T8
BUV395	CD3	BD-563546	UCHT1
BUV496	CD4	BD-612936	SK3
BUV737	CD14	BD-564444	M5E2

Supplemental Table 4: Lymphocyte-oriented Panel (S3)


Fluorochrome	Antigen	Manufacturer/Catalogue #	Clone
FITC	CD38	BD-560982	HIT2
PE	CD5	BD-555353	UCHT2
APC	CD27	BD-558664	M-T271
v450	CD19	BD-560353	HIB19
AF700	CD138	Biolegend-356512	MI15
PerCP-Cy5.5	CD24	BD-561647	ML5
Pe-Cy7	IgD	BD-561314	IA6-2
BV605	PD-1	Biolegend-329924	EH12.2H7
BV786	ALCAM	BD-564939	3A6
BV711	CD8	BD-563677	RPA-T8
BUV395	CD3	BD-563546	UCHT1
BUV496	CD4	BD-612936	SK3
BUV737	CD14	BD-564444	M5E2




Supplemental Figure 1. Populations altered in SARS-CoV-2⁺ patients identified by data-driven (unbiased) analysis. (A) Flow cytometry gating strategy for the selection of events that belong to lymphocyte, monocyte/myeloid and granulocyte before the data-driven analysis. **(B-E)** Box and Whisker plots showing frequencies of selected immune cell populations specifically dysregulated in SARS-CoV-2⁺ patients (CoV-2⁺); **(B)** CoV-2⁺ (red) compared to SARS-CoV-2^{neg} (CoV-2^{neg}, yellow) and healthy controls (HC, blue) (HC $n = 49$; CoV-2^{neg} $n = 21$; CoV-2⁺ $n = 42$), **(C)** according to age groups (HC < 60 y.o. $n = 49$; CoV-2^{neg} hospitalized < 60 y.o. $n = 9$, ≥ 60 y.o. $n = 13$; CoV-2⁺: < 60 y.o. $n = 20$; ≥ 60 y.o. $n = 30$), **(D)** according to disease severity (CoV-2^{neg} mild/moderate disease $n = 8$, severe disease $n = 14$; CoV-2⁺ mild/moderate disease $n = 29$, severe disease $n = 21$), and **(E)** according to the clinical outcome at 30 days in SARS-CoV-2⁺ patients (NIH score 5-8, $n = 36$) vs. (NIH score 1-4, $n = 14$). Mann-Whitney U test (for $n = 2$ categories) and Kruskal-Wallis test (for $n > 2$ categories) followed by a Dunn's post hoc-test were used. ns: not significant.



Supplemental Figure 2. Populations altered in hospitalized patients identified by data-driven (unbiased) analysis. Box and Whisker plots showing frequencies of selected immune cell populations dysregulated in hospitalized patients compared to healthy controls (HC); SARS-CoV-2⁺ (CoV-2⁺, red) compared to SARS-CoV-2^{neg} (CoV-2^{neg}, yellow) and HC (blue) (HC $n = 49$; CoV-2^{neg} $n = 21$; CoV-2⁺ $n = 42$). Mann-Whitney U test (for $n = 2$ categories) and Kruskal-Wallis test (for $n > 2$ categories) followed by a Dunn's post hoc-test were used. ns: not significant.



Supplemental Figure 3. Frequencies of selected immune cell populations identified by conventional analysis. (A-B) Box and Whisker plots showing frequencies of different subsets of immune cell populations in peripheral blood (conventional analysis) from SARS-CoV-2⁺ (CoV-2⁺, red) and SARS-CoV-2^{neg} (CoV-2^{neg}, yellow) hospitalized patients and healthy controls (HC, blue) (A) according to age groups (HC < 60 y.o. $n = 49$; CoV-2^{neg} hospitalized < 60 y.o. $n = 9$, ≥ 60 y.o. $n = 13$; CoV-2⁺: < 60 y.o. $n = 20$, ≥ 60 y.o. $n = 30$), and (B) according to disease severity in hospitalized patients (CoV-2^{neg} mild/moderate disease $n = 8$, severe disease $n = 14$; CoV-2⁺ mild/moderate disease $n = 29$, severe disease $n = 21$). Mann-Whitney U test (for $n = 2$ categories) and Kruskal-Wallis test (for $n > 2$ categories) followed by Dunn's post-hoc test. Each dot represents one donor. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.



Supplemental Figure 4. Multivariate model using random forest class prediction analysis. Results of the top 30 cells population with the greater Gini importance index.